Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ:AMIX) has announced the enrollment and treatment of its first patient in the follow-on phase of its proof-of-concept human clinical trial (PoC 2). This expansion follows positive results from the initial PoC 1 study in patients with severe pancreatic cancer pain.
The PoC 2 phase aims to double the potential addressable market by evaluating the company's nerve ablation technology in additional visceral cancers that signal pain through the Celiac Plexus, as well as earlier stage pancreatic cancers with moderate to severe pain. The technology involves delivering transvascular energy to ablate problematic nerves for pain mitigation.
The company's platform technology has potential applications across multiple indications, including cardiology, hypertension, and chronic pain management. The current PoC 2 phase specifically focuses on interventional cancer pain management applications in areas such as pancreatic, gall bladder, liver, and bile duct cancers, with possibilities for further expansion in oncology and gastroenterology sectors.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,279,889 B2 for its innovative catheter-based platform technology. The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation procedures.
The technology features a catheter-based microchip sensing array antenna designed to detect neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. Key applications include chronic pain management, hypertension treatment, and cardiac modulation. The company plans to submit an IDE and begin U.S. clinical trials in 2025 for pancreatic cancer pain treatment.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,257,071 for its innovative catheter-based platform technology. The patent covers advanced systems combining nerve mapping and radiofrequency (RF) ablation technologies for treating nerve-related conditions. Key features include deployable microfingers with embedded sensors, real-time physiological monitoring, and adaptive modulation capabilities.
The technology utilizes a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity compared to existing solutions. The company's portfolio now includes over 80 issued patents and 40 pending applications. Autonomix plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for treating pancreatic cancer pain.
Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET. During the event, CEO Brad Hauser will provide a corporate overview and discuss the company's innovative catheter-based microchip sensing array technology. This first-in-class platform system aims to enhance neural signal detection and differentiation compared to existing technologies.
The event will include a live interactive Q&A session where investors can submit questions. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days following the event.
Autonomix Medical (NASDAQ: AMIX) has announced plans to initiate a follow-on expansion study (PoC 2) in Q2 2025, following positive results from their initial proof-of-concept trial (PoC 1) for pancreatic cancer pain treatment. The PoC 2 phase will expand testing to include gall bladder, liver, and bile duct cancers, potentially doubling the company's addressable market.
The PoC 1 trial demonstrated significant pain reduction, decreased opioid use, and improved quality of life in late-stage pancreatic cancer patients. The company's smart catheter technology platform shows promise for various applications, including cardiology, hypertension, and chronic pain management. The technology focuses on delivering transvascular energy to ablate problematic nerves for pain mitigation.
Autonomix Medical (NASDAQ: AMIX) has released compelling patient testimonial results from its first-in-human proof-of-concept trial evaluating transvascular nerve ablation for pancreatic cancer pain. The study, which enrolled 20 patients, demonstrated statistically significant pain relief within 24 hours of the procedure.
Key results include: 53.3% pain improvement at 7 days post-procedure (mean pain reduction from 7.81 to 3.65 on VAS scale) and 59.2% improvement at 4-6 weeks (reduction from 7.89 to 3.22). Notably, 100% of responding patients eliminated opioid use at 7 days post-procedure, with 73% remaining opioid-free at 4-6 weeks. The procedure showed a strong safety profile with no serious adverse events.
Based on these positive outcomes, Autonomix is expanding its protocol into PoC 2 phase, including pain management for additional visceral cancers and earlier-stage pancreatic cancer patients.
Autonomix Medical (NASDAQ: AMIX) has participated in a Virtual Investor "What This Means" segment featuring Chief Medical Officer Dr. Robert Schwartz. The discussion focused on two key aspects: the successful completion of their initial first-in-human proof-of-concept trial (PoC 1), which demonstrated meaningful pain reduction, and their plans for a market expansion study (PoC 2). The PoC 2 trial, scheduled to begin in Q2 2025, will evaluate their technology's effectiveness in treating pain across additional visceral cancers and earlier-stage pancreatic cancer. The company's technology focuses on using transvascular energy to ablate problematic nerves for pain mitigation in cancer patients.
Autonomix Medical reports positive outcomes from its first-in-human proof-of-concept trial for pancreatic cancer pain treatment. The study enrolled 20 patients, with 19 receiving treatment through their innovative nerve ablation technology.
Key results include:
- 100% of femoral access patients responded to treatment
- 43.6% pain improvement at 7 days post-procedure
- 49.7% pain improvement at 4-6 weeks
- 100% of responding patients achieved zero opioid use at 7 days
- 73% remained opioid-free at 4-6 weeks
Based on these successful outcomes, Autonomix is expanding its study (PoC 2) to include additional visceral cancers and earlier-stage pancreatic cancer patients. The company's technology shows potential beyond cancer pain management, with possible applications in cardiology, hypertension, and chronic pain management. The expanded trial will begin in Q2 2025.
Autonomix Medical (NASDAQ: AMIX) announced that its technology and early proof-of-concept study results will be showcased at EuroPCR, a leading interventional cardiovascular medicine conference in Paris, France from May 20-23, 2025.
The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis Study', will be featured during PCR Innovators Day. The company's Chief Medical Officer, Dr. Robert S. Schwartz, will be the presenting author of the poster, highlighting Autonomix's developments in precision nerve-targeted treatments.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
